Clinical trials: Nash
Non-alcoholic Fatty Liver Disease, Obesity
A Pilot Study on Whey Protein Supplementation in Non Alcoholic Fatty Liver Disease
An increase in dietary protein intake has been shown to blunt the increase in intrahepatic fat induced by high fat feeding in healthy individuals.
- Trial name
- PROTOB (NCT00870077)
- Testing
- ProWHEY 94 CFM, SponserR
- Where
- Switzerland
- Volunteers
- 11 people
- Sponsor
- University of Lausanne
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
A multi-center evaluation of aldafermin in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis.
- Trial name
- NCT04210245
- Testing
- aldafermin
- Where
- 49 sites in United States, Australia and 7 more
- Volunteers
- 160 people
- Sponsor
- NGM Biopharmaceuticals, Inc
NASH - Nonalcoholic Steatohepatitis
A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH.
- Trial name
- Harmony (NCT04767529)
- Testing
- Efruxifermin
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 128 people
- Sponsor
- Akero Therapeutics, Inc
Epilepsy, Cardiovascular Disease
Impact of Ketogenic Diet on Lipoproteins in Refractory Epilepsy
The ketogenic diet is a non-pharmacological treatment prescribed especially for children and indicated in most specialized centers for patients with refractory epilepsy.
- Conditions
- Epilepsy, Cardiovascular Disease, Non-alcoholic Fatty Liver Disease, Quality of Life
- Trial name
- Ketonutri (NCT02644239)
- Testing
- ketogenic diet
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- University of Sao Paulo
NAFLD, Bariatric Surgery Candidate
The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease
The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease
- Trial name
- NCT04127370
- Testing
- Bariatric Surgery
- Volunteers
- 95 people
- Sponsor
- Assiut University
Healthy Volunteers
Multiple Ascending Dose and DDI Study
Part A will investigate the safety, tolerability, PK and PD of PF-06835919 administered for 14 days in a multiple ascending dose design.
- Trial name
- NCT03031119
- Testing
- PF-06835919, atorvastatin
- Where
- Belgium
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Pfizer
Nonalcoholic Fatty Liver Disease, Obesity
High Fructose Corn Syrup
The purpose of this research study is to learn more about how high fructose corn syrup, a sugar used to sweeten drinks and foods, affects metabolism in obese persons with and without nonalcoholic fatty liver disease.
- Trial name
- Fructose (NCT02018237)
- Testing
- High fructose corn syrup diet, Standard diet (low in high fructose corn syrup)
- Where
- United States
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Evaluate the Physiological Stability of NIS4 Biomarker Between the Fed and Fasting State in Patients With the Target Condition (NAFLD)
Evaluation of the Physiological Stability Variability and Robustness of NIS4
Patients at higher risk of progression to cirrhosis and clinical deleterious outcomes are those that have a high grade of necroinflammation together with significant fibrosis.
- Trial name
- NCT06159257
- Testing
- Blood test
- Where
- France
- Volunteers
- 50 people
- Sponsor
- CerbaXpert
Mafld in Ckd Patients
Association Betweenq MAFLD ( Metabolic Associated Fatty Liver Disease) and Chronic Kidney Disease
Assess frequency of renal affection in mafld
- Trial name
- NCT06135467
- Volunteers
- 150 people
- Sponsor
- Assiut University
Nonalcoholic Steatohepatitis (NASH)
A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an Extension
This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension.
- Trial name
- NCT04880031
- Testing
- Efimosfermin
- Where
- 48 sites in United States
- Volunteers
- 231 people
- Sponsor
- GlaxoSmithKline
Chronic Kidney Diseases, NAFLD
Chronic Kidney Disease and Non-alcoholic Fatty Liver Diseases
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. This disease reportedly affects up to 30% of the general population in Western countries, especially in patients with…
- Trial name
- NAFLD (NCT04779905)
- Testing
- urinary albumbin/creatinine ratio
- Where
- Egypt
- Volunteers
- 62 people
- Sponsor
- Sohag University
NAFLD, Obesity
Vigabatrin and Insulin Sensitivity
Nonalcoholic fatty liver disease (NAFLD) is a common complication of obesity and is associated with an increased risk of developing type 2 diabetes.
- Trial name
- NCT04321395
- Testing
- Vigabatrin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Nonalcoholic Steatohepatitis (NASH) With Fibrosis
A Study to Evaluate the Efficacy and Safety of JKB-122 in Patients With NASH and Fibrosis
A double-blind placebo controlled randomized Phase 2 study to determine if JKB-122 compared with placebo resolves NASH on liver biopsy and improves fibrosis
- Trial name
- NCT04255069
- Testing
- Dose 1 JKB-122, Dose 2 JKB-122
- Volunteers
- 300 people
- Sponsor
- TaiwanJ Pharmaceuticals Co., Ltd
Diabete Type 2, Non Alcoholic Fatty Liver
Comparative Effects of Aspirin, Metformin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD), currently referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common hepatic manifestation of metabolic dysfunction and may progress from simple…
- Trial name
- AS-NAFLD (NCT07338331)
- Testing
- Aspirin, Dapagliflozin (10Mg Tab) along with standard medical therapy, Metformin 1000 mg
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Galala University
NAFLD, Diabetes Mellitus
Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes
The primary objective of this pilot study is to assess the feasibility and acceptability of an intervention for improved detection and evidence-based care of NAFLD in Latinx and Black patients with type 2 diabetes (T2D) in Duke…
- Trial name
- NAFLD-DM (NCT05844137)
- Testing
- NAFLD Education, diet/lifestyle support, T2D medication management
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Nonalcoholic Steatohepatitis (NASH)
Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate the safety and tolerability of GS-9674 in participants with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT02854605
- Testing
- GS-9674
- Where
- 37 sites in United States, Canada and 4 more
- Volunteers
- 140 people
- Sponsor
- Gilead Sciences
Steatohepatitis, Nonalcoholic
Screening for Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) at Al-Rajhy Hospital Nutrition Clinic. Assiut, Egypt
Primary outcome Screen for MAFLD among patients attending to the Nutrition clinic in Al Rajhi hospital. Secondary outcome Determining the degrees of fibrosis and steatosis in patients with MAFLD Determining the rate of obesity…
- Trial name
- NCT04861012
- Testing
- Ultrasound
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Assiut University
NAFLD, Obesity
RCT of Caloric Restriction vs. Alternate-Day Fasting in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) in patients with diabetes (T2DM) is increasing in prevalence and can lead to cirrhosis.
- Conditions
- NAFLD, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT03365531
- Testing
- Alternate Daily Fasting (ADF), Caloric Restriction (CR)
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Florida
Coronary Disease, Non-alcoholic Fatty Liver Disease
Non-invasive Liver Screening for Risk Assessment for Coronary Heart Disease
Background: Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome, which is one of the major risk factors of coronary heart disease (CHD).
- Conditions
- Coronary Disease, Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques
- Trial name
- NILS-R-CHD (NCT02779946)
- Testing
- Fibro Scan, PNPLA3
- Where
- Germany
- Volunteers
- 216 people
- Sponsor
- University of Leipzig
Hyperoxaluria, Nonalcoholic Fatty Liver Disease
A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria
The purpose of this study is to test the safety of BMN 255 and to learn about the effect BMN 255 has on you and your hyperoxaluria associated with NAFLD, and compare these effects with a placebo.
- Conditions
- Hyperoxaluria, Nonalcoholic Fatty Liver Disease, Kidney Stone
- Trial name
- NCT06138327
- Testing
- BMN 255
- Where
- 7 sites in United States
- Sponsor
- BioMarin Pharmaceutical